ESRRA and cancer: Since chemical XCT790 (XCT for short) acts as an ERRα (estrogen-related receptor α) inverse agonist and has been demonstrated to drastically interfere with mitochondrial biogenesis in cancer cells [32], illustrated in Fig. S4A, we tested the effect of XCT to assess the role of mitochondrial homeostasis in DE differentiation.